Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Equillium, Inc.NASDAQ: EQ
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 322.9% from a year ago
Cash & equivalents stood at $61.32M at the end of Q1 FY2026, up 322.9% from a year earlier and up 102.5% from the prior quarter. Over 3 fiscal years it compounded at -20.0% a year.
Context
- Cash & equivalents amounted to 97.2% of total assets at the end of Q1 FY2026, up 10.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +322.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 30.28M USD
- Year-over-year change
- +67.4%
- 4-year CAGR
- -11.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.28M | +67.4% |
| FY2024 | 2024-12-31 | 18.09M | -22.1% |
| FY2023 | 2023-12-31 | 23.22M | -60.7% |
| FY2022 | 2022-12-31 | 59.11M | +17.4% |
| FY2021 | 2021-12-31 | 50.37M | — |
Cash & Equivalents vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's Mar 2026 cash & equivalents of $61.32M is the 3rd highest of the 10 companies compared; the peer median is $16.38M.
- Its year-over-year change of +322.9% is the 3rd highest of 10, against a peer median of +24.7%.
- Cash & equivalents amounts to 97.2% of total assets for EQ, versus a peer median of 56.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | Mar 2026 | $917.55M | +30783.5% | +1063.1% | 12570.5% |
| Mar 2026 | $255.84M | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Mar 2026 | $51.05M | -1.6% | -9.8% | 15.6% | |
| Mar 2026 | $16.38M | +24.7% | -19.3% | 53.0% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Mar 2026 | $5.56M | +1279.8% | +1625.2% | 96.0% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding EQ) | $16.38M | +24.7% | -9.8% | 56.4% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M |
| Short-term Investments | 30.35M | 11.92M | 17.65M | 4.49M | 0 |
| Net Receivables | 0 | 4.11M | 6.29M | 1.14M | 108K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8K | 235K | 429K | (547K) |
| Total Current Assets | 83.37M | 76.74M | 49.35M | 24.98M | 30.28M |
| Property, Plant & Equipment (Net) | 1.88M | 1.58M | 1.11M | 626K | 658K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 153K | 104K | 70K | 0 | 0 |
| Total Non-current Assets | 2.04M | 1.69M | 1.18M | 626K | 658K |
| Total Assets | 85.41M | 78.42M | 50.53M | 25.6M | 31.89M |
| Account Payables | 1.23M | 3.98M | 4.71M | 2.68M | 755K |
| Short-term Debt | 1.43M | 5.71M | 0 | 197K | 363K |
| Tax Payables | 0 | 0 | 0 | 365K | 0 |
| Deferred Revenue | 0 | 14.7M | 15.73M | 0 | 0 |
| Other Current Liabilities | 3.38M | 0 | 3.64M | 2.68M | 1.82M |
| Total Current Liabilities | 8.92M | 32.04M | 27.57M | 6.36M | 2.93M |
| Long-term Debt | 8.75M | 3.24M | 0 | 0 | 356K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 10.38M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 9.99M | 14.44M | 384K | 187K | 356K |
| Total Liabilities | 18.9M | 46.48M | 27.96M | 6.54M | 3.29M |
| Common Stock | 2K | 3K | 3K | 3K | 5K |
| Retained Earnings | (109.98M) | (172.41M) | (185.74M) | (193.81M) | (216.21M) |
| Accumulated OCI | (138K) | 76K | 140K | 781K | 363K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 66.51M | 31.94M | 22.57M | 19.06M | 28.6M |
| Total Debt | 11.79M | 10.19M | 824K | 384K | 719K |
| Net Debt | (38.58M) | (48.92M) | (22.39M) | (17.7M) | (29.56M) |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.